Zuranolone

In a bittersweet decision for Biogen and Sage Therapeutics, the FDA approved the fast-acting drug zuranolone as the first tablet for postpartum depression on 04 August —but rejected the drug for major depressive disorder treatment. Zurzuvae is a neuroactive steroid that acts as a GABA-A receptor-positive allosteric...